Cafeity Get the app

Side effects

Heartburn, reflux and indigestion on a GLP-1

A stomach that empties more slowly is a stomach that is full for longer, and for some people that means acid where it should not be — usually in the evening, usually after a bigger meal. The labels record it, and the fixes are mostly about how and when you eat.

By the Cafeity teamUpdated 4 min read

The short answer

Indigestion and reflux are listed side effects of GLP-1 medicines. In the weight-management trials, indigestion (dyspepsia) was reported by 9% on semaglutide 2.4 mg against 3% on placebo, up to 10% on tirzepatide against 4%, 9.6% on liraglutide 3 mg against 2.7%, and up to 16% on orforglipron against 4%; reflux (GERD) by 4–7% against 2–3%.1234 Smaller meals, less fat, not lying down soon after eating and limiting alcohol are the usual first steps. Trouble swallowing, vomiting blood or black stools need urgent attention, and chest pain should never be assumed to be heartburn.

Bar chart of indigestion (dyspepsia) in the weight-management trials: Semaglutide 2.4 mg 9% versus 3% on placebo; Tirzepatide 10% versus 4% on placebo; Liraglutide 3 mg 9.6% versus 2.7% on placebo; Orforglipron 16% versus 4% on placebo.
Share of trial participants who reported indigestion, from each label. Not a head-to-head comparison.

How common it is

Indigestion (dyspepsia)

Indigestion (dyspepsia) in placebo-controlled trials, from the current US prescribing information for each medicine. Rates from different medicines' trials are not directly comparable.
Medicine (trial population)PlaceboMedicine
Semaglutide 2.4 mg weekly injection (adults with obesity or overweight)3%9%
Tirzepatide weekly injection (adults with obesity or overweight)4%9% (5 mg), 9% (10 mg), 10% (15 mg)
Liraglutide 3 mg daily injection (adults with overweight or obesity)2.7%9.6%
Orforglipron daily tablet (adults with obesity or overweight)4%12% (5.5 mg), 16% (9 mg), 13% (17.2 mg)
Tirzepatide weekly injection (type 2 diabetes) (adults with type 2 diabetes)3%8% (5 mg), 8% (10 mg), 5% (15 mg)
Dulaglutide weekly injection (adults with type 2 diabetes)2.3%4.1% (0.75 mg), 5.8% (1.5 mg)
Liraglutide daily injection (type 2 diabetes) (adults with type 2 diabetes)1%4% (1.2 mg), 7% (1.8 mg)
Exenatide twice-daily injection (adults with type 2 diabetes)3%6%

Reflux (gastro-oesophageal reflux disease)

Reflux (GERD) in placebo-controlled trials, from the current US prescribing information for each medicine. Rates from different medicines' trials are not directly comparable.
Medicine (trial population)PlaceboMedicine
Semaglutide 2.4 mg weekly injection (adults with obesity or overweight)3%5%
Tirzepatide weekly injection (adults with obesity or overweight)2%4% (5 mg), 4% (10 mg), 5% (15 mg)
Liraglutide 3 mg daily injection (adults with overweight or obesity)1.7%4.7%
Orforglipron daily tablet (adults with obesity or overweight)2%6% (5.5 mg), 6% (9 mg), 7% (17.2 mg)
Exenatide twice-daily injection (adults with type 2 diabetes)1%3%

Why it happens

These medicines slow gastric emptying — for tirzepatide the label notes the effect is largest after the first dose and lessens over time.12 Food that stays in the stomach longer keeps it fuller and more acidic for longer, which makes reflux more likely, particularly when lying down. Burping often comes with it; see sulphur burps.

What tends to help

  • Smaller meals, so there is less in the stomach at once.5
  • Less fatty and fried food, which empties more slowly.
  • An earlier, lighter evening meal, and not lying down for a few hours after eating.
  • Limiting alcohol, which the 2025 joint advisory notes may worsen nausea and reflux on these medicines.5
  • Asking a pharmacist about antacids or other over-the-counter treatment — and mentioning your GLP-1, since these medicines can affect how some tablets are absorbed.4

When to contact your prescriber

Keeping a record of it

Log heartburn and indigestion with a severity and a time, on the same timeline as your doses, meals and fluids. After a few weeks the record shows whether it follows dose increases, particular foods or the days after an injection — and the Visit Summary puts that on one page for your prescriber.

Cafeity dose screen: an estimated medication-level curve labelled "Estimate based on published half-life. Not a measurement", the last dose, the injection site (stomach, lower left), a countdown to the next scheduled dose and a side-effect check-in.
A side-effect check-in under every dose.
Cafeity "Your week, understood" screen: Ora explains that everything is calculated from your own log, offers questions such as "When are my symptoms worst?", and shows the week's protein, energy, water, weight trend, symptom days and a note that protein was 80 g under target.
Ask when your symptoms are worst.

Download Cafeity on the App Store

Common questions

Can GLP-1 medicines cause acid reflux?
Yes. Reflux and indigestion are listed reactions on the weight-management labels, reported more often than on placebo.12
Why is my reflux worse at night?
A slower-emptying stomach can still be full hours after dinner, and lying down makes reflux easier. An earlier, smaller evening meal often helps.
Can I take antacids with a GLP-1?
Ask a pharmacist, and tell them about your GLP-1 — these medicines slow stomach emptying, which can affect other oral medicines.4

Sources

  1. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026
  2. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  3. Liraglutide 3 mg injection for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 15 June 2026
  4. Orforglipron tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 13 August 2026
  5. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society Mozaffarian D et al. 2025 (published in four journals)

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.